Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

News

Meetings
New York Valves 2024 Late-Breaking Clinical Trials and Science Announced
05/22/2024

Cardiovascular Research Foundation News

Cardiovascular Research Foundation Ne...
The late-breaking clinical research that will be presented at New York Valves will unveil the latest advances in transcatheter aortic valve replacement, alongside innovations in mitral and tricuspid devices and techniques.
The late-breaking clinical research that will be presented at New York Valves will unveil the latest advances in transcatheter aortic valve replacement, alongside innovations in mitral and tricuspid devices and techniques.
The late-breaking clinical...
05/22/2024
Cath Lab Digest
Inflammation
Researchers Mapped Immune Response in Heart Attacks and Identified Signatures Correlating With Clinical Progression
05/22/2024

Ludwig-Maximilians-Universität München News

Ludwig-Maximilians-Universität Münche...
According to findings from animal studies, the inflammatory reaction plays an important role after an infarction and has a decisive influence on whether the functions of the heart muscle are restored.
According to findings from animal studies, the inflammatory reaction plays an important role after an infarction and has a decisive influence on whether the functions of the heart muscle are restored.
According to findings from...
05/22/2024
Cath Lab Digest
Drugs
Scientists’ Discovery Could Reduce Dependence on Animals for Heparin
05/21/2024

Rensselaer Polytechnic Institute News

Rensselaer Polytechnic Institute News...
“In recent years, with disease and contamination issues disrupting the global supply chain of pig heparin and potentially putting millions of patients at risk, it’s clear we need to diversify the way we make this drug,” said Jonathan Dordick,...
“In recent years, with disease and contamination issues disrupting the global supply chain of pig heparin and potentially putting millions of patients at risk, it’s clear we need to diversify the way we make this drug,” said Jonathan Dordick,...
“In recent years, with disease...
05/21/2024
Cath Lab Digest

Advertisement

hypertension
Evening Aerobic Exercise Benefits Elderly Hypertensives More Than Morning Exercise
05/21/2024

Fundação de Amparo à Pesquisa do Estado de São Paulo News

Fundação de Amparo à Pesquisa do Esta...
Aerobic training is known to regulate blood pressure more effectively when practiced in the evening than in the morning. Researchers who conducted a study of elderly patients at the University of São Paulo’s School of Physical Education and...
Aerobic training is known to regulate blood pressure more effectively when practiced in the evening than in the morning. Researchers who conducted a study of elderly patients at the University of São Paulo’s School of Physical Education and...
Aerobic training is known to...
05/21/2024
Cath Lab Digest
Pulmonary Hypertension
Hormone Replacement Therapy (HRT) May Improve Pulmonary Hypertension and Right Ventricular Function
05/20/2024

American Thoracic Society News

American Thoracic Society News ...
The results: Across all pulmonary hypertension groups, average pulmonary arterial pressure decreased with greater lifetime duration of menses. Use of HRT was associated with lower mean pulmonary artery pressure and higher right ventricular...
The results: Across all pulmonary hypertension groups, average pulmonary arterial pressure decreased with greater lifetime duration of menses. Use of HRT was associated with lower mean pulmonary artery pressure and higher right ventricular...
The results: Across all...
05/20/2024
Cath Lab Digest
Transcatheter Heart Valves
LANDMARK Trial: Meril Announces Successful Primary Outcomes of Next-Gen Myval THV Series in Major RCT
05/17/2024

Meril Life Sciences News

Meril Life Sciences News
Professor Serruys, Chairman & study director of the LANDMARK trial, said, "Myval THV series are novel next-gen THV devices; non-inferior to the Sapien and Evolut THV series. Myval THV series have a unique size matrix incorporating...
Professor Serruys, Chairman & study director of the LANDMARK trial, said, "Myval THV series are novel next-gen THV devices; non-inferior to the Sapien and Evolut THV series. Myval THV series have a unique size matrix incorporating...
Professor Serruys, Chairman &...
05/17/2024
Cath Lab Digest

Advertisement

Heart Failure
Implicity Earns FDA Clearance for New Heart Failure Prediction Algorithm
05/17/2024

Implicity News

Implicity News
SignalHF is unique in that the manufacturer-agnostic solution can be used to analyze data collected from a variety of CIEDs, including implantable cardiac defibrillators (ICD), pacemakers (PM) and cardiac resynchronization therapy devices...
SignalHF is unique in that the manufacturer-agnostic solution can be used to analyze data collected from a variety of CIEDs, including implantable cardiac defibrillators (ICD), pacemakers (PM) and cardiac resynchronization therapy devices...
SignalHF is unique in that the...
05/17/2024
Cath Lab Digest
Coronary Implants
DESyne BDS Plus RCT: Late-Breaking 12-Month Data Demonstrate Significant Improvement in Safety and Effectiveness of World’s First Site-Specific Antithrombotic Therapeutic Compared to DES
05/16/2024

Elixir Medical News

Elixir Medical News
DESyne BDS Plus has a bioresorbable coating containing three drugs: two anticoagulants (rivaroxaban and argatroban) and an antiproliferative mTOR inhibitor (sirolimus) designed for delivery of site-specific antithrombotic therapeutic.
DESyne BDS Plus has a bioresorbable coating containing three drugs: two anticoagulants (rivaroxaban and argatroban) and an antiproliferative mTOR inhibitor (sirolimus) designed for delivery of site-specific antithrombotic therapeutic.
DESyne BDS Plus has a...
05/16/2024
Cath Lab Digest
Intravascular Lithotripsy
Primary Outcomes From PINNACLE I Clinical Trial Establish Safety and Effectiveness of Elixir Medical’s Hertz Contact IVL in Moderate to Severe Calcified Coronary Artery Lesions
05/16/2024

Elixir Medical News

Elixir Medical News
The novel LithiX Hertz Contact Intravascular Lithotripsy (IVL) system is designed to address challenges associated with the percutaneous treatment of nodular, concentric, and eccentric moderate to severe calcified lesions resistant to optimal...
The novel LithiX Hertz Contact Intravascular Lithotripsy (IVL) system is designed to address challenges associated with the percutaneous treatment of nodular, concentric, and eccentric moderate to severe calcified lesions resistant to optimal...
The novel LithiX Hertz Contact...
05/16/2024
Cath Lab Digest

Advertisement

Bioadaptors
BIOADAPTOR RCT Data Demonstrate Significant Clinical Advantage of Elixir Medical’s DynamX Bioadaptor Over Standard of Care Drug-Eluting Stent at Two Years
05/16/2024

Elixir Medical News

Elixir Medical News
Elixir Medical announced two-year results from the BIOADAPTOR randomized controlled (1:1) trial, comparing the DynamX® Coronary Bioadaptor System to standard of care Resolute Onyx™ Drug-Eluting Stent from 34 centers in Japan, Europe, and New...
Elixir Medical announced two-year results from the BIOADAPTOR randomized controlled (1:1) trial, comparing the DynamX® Coronary Bioadaptor System to standard of care Resolute Onyx™ Drug-Eluting Stent from 34 centers in Japan, Europe, and New...
Elixir Medical announced...
05/16/2024
Cath Lab Digest

Advertisement

Advertisement

Subscriber

Cath Lab Digest Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use